Rockin Robin SongFlying The Web For News.
RobinPost Logo Amazon Prime Deals





Globe NewsWire News Distribution Service


CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025, in line with prior financial guidance.


Posted: 2026-01-11 20:00:00

Get Full News Story On GlobeNewsWire Press Release Service



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.



More News From This Category
Press Release: Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
Sun, 11 Jan 2026 23:07:40 +0000

TEL AVIV, Israel, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will present its ongoing transformation and expected growth trajectory through 2030 at the 44th Annual J.P. Morgan Healthcare Conference. Teva’s President and Chief Executive Officer, Richard Francis, will meet with investors and present the Company’s milestones achieved in…

Read More ...


Press Release: Bronstein, Gewirtz & Grossman LLC Urges Smartsheet Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Sun, 11 Jan 2026 17:07:41 +0000

NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed on behalf of all former stockholders of Smartsheet Inc. (NYSE: SMAR) in connection with the January 2025 sale (the “Merger” or “Buyout”) of Smartsheet to affiliates of…

Read More ...


Press Release: Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
Sun, 11 Jan 2026 14:07:42 +0000

• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and total dysphagic symptom burden as compared to the 12-month follow-up timepoint

Read More ...


Press Release: Mutuum Finance (MUTM) Reports Ongoing Roadmap Progress With Halborn Security Audit Finalized
Sun, 11 Jan 2026 11:07:41 +0000

DUBAI, United Arab Emirates, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Mutuum Finance (MUTM) has provided a new update on its technical roadmap as development for its decentralized lending protocol continues. The team confirmed that security auditing has progressed as planned and that work on the first public version of the protocol is moving forward. Mutuum…

Read More ...


Related Bing News Results





















Blow Us A Whistle


Related Product Search/Búsqueda de productos relacionados

Amazon Logo